Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTXNYSE / NASDAQHealthcareSmall cap

$39.90-$1.26 (-3.1%)

Last close · Data as of Nov 20, 2026

Market cap
$4.0B
P/E
-23.9x
EV / EBITDA
-20.9x
Revenue
$0.00
ROCE
-36.4%

+79.3% over the last year

Edgewise Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.4%
3M
-7.8%
6M
+21.6%
1Y
+79.3%
5Y
+100.1%

52-week range

Day change -$1.26 (-3.1%) from $41 to $40 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in EWTX, bought on each weekday since 2021.

News & filings

What Edgewise Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 168 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

Read moreShow less

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Sector
Healthcare
Shares outstanding
106.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.0B
P/E
-23.9x
P/B
7.7x
EV / EBITDA
-20.9x
52-week high
$48.74
52-week low
$20.94

Profitability

ROE
-32.1%
ROCE
-36.4%
ROIC
-32.5%
ROA
-30.4%

Growth

Revenue
$0.00
Net profit growth, 1Y
25.4%
Free cash flow
-$144.1M

Solvency

Current ratio
19.85
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.86
Cash / Market cap
1.5%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Edgewise Therapeutics, Inc. revenue and net profit by fiscal year
Edgewise Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$67.6M
FY2023$0.00-$100.2M
FY2024$0.00-$133.8M
FY2025$0.00-$167.8M

Cash flows

FY2025: -$143.8M from operations, -$144.1M free after investment (dashed).

Edgewise Therapeutics, Inc. operating and free cash flow by fiscal year
Edgewise Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$52.6M-$58.2M
FY2023-$91.9M-$97.7M
FY2024-$109.0M-$110.3M
FY2025-$143.8M-$144.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$189.1M
Net profit
-$167.8M
Cash from operations
-$143.8M
Free cash flow
-$144.1M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$189.1M-$167.8M-$144.1M-32.1%—+25.4%

Monthly returns

Month-by-month returns of EWTX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$552.6M
Liabilities$30.4M
Equity$522.3M
Paid-in capital$1.1B
Retained earnings-$546.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; EWTX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

Not shown (no positive earnings and no EV / Sales): Edgewise Therapeutics, Inc., Celcuity Inc., Erasca, Inc., Oruka Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Edgewise Therapeutics, Inc.EWTXthis company$4.0B-23.9x7.7x-32.1%-20.9x
Celcuity Inc.CELC$4.5B-25.5x44.8x-176.1%-29.2x
Travere Therapeutics, Inc.TVTX$4.3B-168.1x37.4x-22.2%203.9x
10x Genomics, Inc.TXG$4.3B-97.7x5.3x-5.5%988.3x
Erasca, Inc.ERAS$4.1B-33.1x12.7x-38.3%-32.0x
LivaNova PLCLIVN$4.0B-16.7x3.4x-20.2%-34.4x
Oruka Therapeutics, Inc.ORKA$3.8B—9.9x-22.5%—
Crinetics Pharmaceuticals, Inc.CRNX$3.7B-7.8x3.7x-46.9%-7.0x
iRhythm Holdings, Inc.IRTC$3.5B-79.2x23.1x-29.2%-1014.6x
Peer median—-33.1x11.3x-25.8%-29.2x

Year-to-date ROI

EWTX since 1 January, against earlier years.

Historical volatility

EWTX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$191.4M
Research and developmentResearch And Development$151.4M
Total expensesTotal Expenses$191.4M
Pretax incomePretax Income-$167.8M

Learn while you research

Academy chapters picked for Edgewise Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →